https://orcid.org/0000-0003-4119-5230
References
- Bacharach J, Lee WW, Harrison AR, Freddo TF. A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options. Eye. 2021;35(9):2468–2481. doi:10.1038/s41433-021-01547-5
- Kim MH, Cho J, Zhao D, et al. Prevalence and associated factors of blepharoptosis in Korean adult population: the Korea National Health and Nutrition Examination Survey 2008–2011. Eye. 2017;31(6):940–946. doi:10.1038/eye.2017.43
- Hashemi H, Khabazkhoob M, Emamian MH, et al. The prevalence of ptosis in an Iranian adult population. J Curr Ophthalmol. 2016;28(3):142–145. doi:10.1016/j.joco.2016.04.005
- Sridharan GV, Tallis RC, Leatherbarrow B, Forman WM. A community survey of ptosis of the eyelid and pupil size of elderly people. Age Ageing. 1995;24(1):21–24. doi:10.1093/ageing/24.1.21
- Meyer DR, Stern JH, Jarvis JM, Lininger LL. Evaluating the visual field effects of blepharoptosis using automated static perimetry. Ophthalmology. 1993;100(5):651–658; discussion 658–659. doi:10.1016/S0161-6420(93)31593-9
- Nichols KK, Malloy KA, Karpecki PM, et al. Topical review: an update of diagnostic and management algorithms for acquired blepharoptosis. Optom Vis Sci. 2022;99(3):230–240. doi:10.1097/OPX.0000000000001868
- Cahill KV, Bradley EA, Meyer DR, et al. Functional indications for upper eyelid ptosis and blepharoplasty surgery: a report by the American Academy of Ophthalmology. Ophthalmology. 2011;118(12):2510–2517. doi:10.1016/j.ophtha.2011.09.029
- Lim JM, Hou JH, Singa RM, Aakalu VK, Setabutr P. Relative incidence of blepharoptosis subtypes in an oculoplastics practice at a tertiary care center. Orbit. 2013;32(4):231–234. doi:10.3109/01676830.2013.788673
- Bacharach J, Wirta DL, Smyth-Medina R, et al. Rapid and sustained eyelid elevation in acquired blepharoptosis with oxymetazoline 0.1%: randomized Phase 3 trial results. Clin Ophthalmol. 2021;15:2743–2751. doi:10.2147/OPTH.S306155
- Wirta DL, Korenfeld MS, Foster S, et al. Safety of once-daily oxymetazoline hcl ophthalmic solution, 0.1% in patients with acquired blepharoptosis: results from four randomized, double-masked clinical trials. Clin Ophthalmol. 2021;15:4035–4048. doi:10.2147/OPTH.S322326
- Slonim CB, Foster S, Jaros M, et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020;138(11):1168–1175. doi:10.1001/jamaophthalmol.2020.3812